NOW AVAILABLE AT JADE NEXUS http://jadenexus.net/?ref=KRISTINA 40% OFF 💥INCLUDING VIAL SETS💥 WITH CODE: KRISTINA Survodutide is an investigational once-weekly peptide that acts as a dual GLP-1 receptor and glucagon receptor agonist. Unlike Tirzepatide (GLP-1/GIP), Survodutide combines appetite suppression from GLP-1 with increased energy expenditure and fat metabolism from glucagon receptor activation. Potential Benefits: 1. Significant Weight Loss In clinical trials, participants achieved approximately 16–19% average body weight reduction, placing Survodutide among the more effective obesity medications currently in development. 2. Reduction in Visceral ("Belly") Fat Survodutide appears particularly effective at reducing visceral adipose tissue, the metabolically harmful fat surrounding organs. MRI analyses demonstrated reductions of up to 34% in visceral fat. 3. Dramatic Liver Fat Reduction One of survodutide's most impressive findings has been its impact on fatty liver disease. Clinical studies have shown: - Up to 63% reduction in liver fat - Improvement in markers of liver inflammation and fibrosis - Potential benefit for MASLD/MASH patients 4. Preservation of Lean Mass Unlike some weight-loss therapies where muscle loss can be significant, survodutide appears to preserve lean body mass relatively well while preferentially reducing fat mass. 5. Cardiometabolic Improvements Studies have demonstrated improvements in: - Blood glucose - Insulin sensitivity - Lipid markers - Cardiovascular risk factors - Liver enzymes ******************************************************************************************************** 10mg vial + 2.0mL bac water Concentration: 5mg/mL Week 1-4 0.6 mg weekly (12 units) Week 5-8 1.2 mg weekly (24 units) Week 9-12 1.8 mg weekly (36 units) Week 13-16 2.4 mg weekly (48 units) Week 17-20 3.0 mg weekly (60 units) Week 21-24 3.6 mg weekly (72 units) Week 25-28 4.8 mg weekly (96 units)